Body fat distribution has no effect on serum visfatin levels in healthy female subjects

Cytokine

Volumn 49, Issue 3, 2010, Pages 275-278

  Ersoy, Canan ^a   Sadikoglu, Ganime ^a   Orhan, Hasan ^a   Guclu, Metin ^a   Sarandol, Emre ^a   Akgun, Meral Demirci ^a   Ozcakir, Alis ^a   Imamoglu, Sazi ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

General obesity; Visceral obesity; Visfatin

Indexed keywords

NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE;

ADULT; ARTICLE; BODY FAT DISTRIBUTION; BODY MASS; CONTROLLED STUDY; CORRELATIONAL STUDY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; INSULIN RESISTANCE; METABOLIC PARAMETERS; NORMAL HUMAN; OBESITY; PATIENT ASSESSMENT; PATIENT IDENTIFICATION; PRIORITY JOURNAL; WAIST CIRCUMFERENCE;

ADULT; BLOOD GLUCOSE; BODY FAT DISTRIBUTION; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY; PROSPECTIVE STUDIES; WAIST CIRCUMFERENCE;

RODENTIA;

EID: 75449085490     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2009.11.011     Document Type: Article

References (21)

1. Hellerstein M.K., and Parks E.J. Obesity and overweight. In: Gardner D.G., and Shoback D. (Eds). Greenspan's basic and clinical endocrinology. 8th ed. (2007), McGraw Hill Companies, USA 796-816
2. Chen C.C., Li T.C., Li C.I., Liu C.S., Lin W.Y., Wu M.T., et al. The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women. Metabolism 56 (2007) 1216-1220
3. Filippatos T.D., Derdemezis C.S., Gazi I.F., Lagos K., Kiortsis D.N., Tselepis A.D., et al. Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest 38 (2008) 71-72
4. Marcinkowska M., Lewandowski K.C., Lewiński A., Bieńkiewicz M., Basińska-Lewandowska M., Salata I., et al. Visfatin levels do not change after the oral glucose tolerance test and after a dexamethasone-induced increase in insulin resistance in humans. Endokrynol Pol 58 (2007) 188-194
5. Araki S., Dobashi K., Kubo K., Kawagoe R., Yamamoto Y., Kawada Y., et al. Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children. Obesity (Silver Spring) 16 (2008) 384-388
6. Stewart A.L., and Brook R.H. Effects of being overweight. Am J Public Health 73 (1983) 171-178
7. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
8. Lebovitz H.E. Clinician's manual of insulin resistance (2002), Science Press, London, UK
9. Wajchenberg B.L. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 21 (2000) 697-738
10. Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307 (2005) 426-430
11. Yang W.S., Lee W.J., Funahashi T., Tanaka S., Matsuzawa Y., Chao C.L., et al. Plasma adiponectin levels in overweight and obese Asians. Obes Res 10 (2002) 1104-1110
12. Jian W.X., Luo T.H., Gu Y.Y., Zhang H.L., Zheng S., Dai M., et al. The visfatin gene is associated with glucose and lipid metabolism in a Chinese population. Diabet Med 23 (2006) 967-973
13. Sandeep S., Velmurugan K., Deepa R., and Mohan V. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism 56 (2007) 565-570
14. Berndt J., Klöting N., Kralisch S., Kovacs P., Fasshauer M., Schön M.R., et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 54 (2005) 2911-2916
15. Dogru T., Sonmez A., Tasci I., Bozoglu E., Yilmaz M.I., Genc H., et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 76 (2007) 24-29
16. Pagano C., Pilon C., Olivieri M., Mason P., Fabris R., Serra R., et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 91 (2006) 3165-3170
17. Dogru T., Sonmez A., Tasci I., Yilmaz M.I., Erdem G., Erturk H., et al. Plasma visfatin levels in young male patients with uncomplicated and newly diagnosed hypertension. J Hum Hypertens 21 (2007) 173-175
18. Chen M.P., Chung F.M., Chang D.M., Tsai J.C., Huang H.F., Shin S.J., et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91 (2006) 295-299
19. Brousseau M.E., Schaefer E.J., Wolfe M.L., Bloedon L.T., Digenio A.G., Clark R.W., et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350 (2004) 1505-1515
20. Arya R., Blangero J., Williams K., Almasy L., Dyer T.D., Leach R.J., et al. Factors of insulin resistance syndrome - related phenotypes are linked to genetic locations on chromosomes 6 and 7 in nondiabetic Mexican-Americans. Diabetes 51 (2002) 841-847
21. Oki K., Yamane K., Kamei N., Nojima H., and Kohno N. Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol (Oxf) 67 (2007) 796-800